Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681011 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL22013593 | 0.78 | CACNA1G (0.36) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL25033758 | 0.73 | CACNA1G (0.40) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL68235 | 0.72 | CACNA1G (0.39) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL25033756 | 0.71 | CACNA1G (0.35) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL22012760 | 0.70 | HTR2C (0.34) | CACNA1GCACNA1BCACNA1CHTR2CSLC6A4 | |
| SCHEMBL30466792 | 0.69 | RIPK1 (0.41) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL19950236 | 0.68 | CLK1 (0.45) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL30466777 | 0.68 | AR (0.44) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C | |
| SCHEMBL31137753 | 0.68 | RIPK1 (0.47) | CACNA1GCACNA1BCACNA1CRIPK1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CACNA1G 3288/4885CACNA1B 2816/4885CACNA1C 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.